Physostigmine Research Paper

The FDA recently has allowed two treatments to be used for Alzheimer patients. One of the treatments is a Partial Glutamate Antagonist, which is an important transmitter to the brain. It is said that Glutamate helps patients more than sugar pills do, however; it is said that too much

They studied this drug over the course of two months by comparing a group of normal mice to two groups that have been engineered to emulate symptoms of Alzheimer’s such as the memory loss and presences amyloid plaques in the brain among others. One of these groups was treated with the TA while the other was not.

The experiment was conducted within a year, which involved one hundred and twenty patients within the ages of fifty and above. These participants showed signs of acquiring Alzheimer’s disease due to the fact that they experienced a minor condition of dementia. The experiment was led in a double blind manner where both the subjects and researchers do not know which type of treatment the participants received. The participants were divided into two groups, an experimental group and a control group. The experimental group received the capsule

“I learned that courage was not the absence of fear, but the triumph over it. The brave man is not he who does not feel afraid, but he who conquers that fear. ”(Nelson Mandela) Santiago surpasses many hardships while being courageous, brave, and being a real friend. The themes in all his stories are the same.

Before an investigational study on a new drug may take place, research subjects must submit informed consent and informed of all possible risks and benefits of the therapy. There are four types of phases associated with investigational studies that may occur. Beginning with the first phase, a Phase I study consist of few healthy participants who do not have the disease that the certain drug is said to treat. The purpose of this phase is to determine the optimal dosage range and the pharmacokinetics of the drug and if further testing of the drug is necessary. Vital signs, blood tests, urinary analysis, and other specific monitoring exams are performed. The next phase, Phase II, also involves a relatively small number of participants who this time have the disease that the drug is designed to treat. Participants are closely monitored to determine the effects and adverse

Alzheimer’s disease is the most common form of dementia, which slowly and steadily impairs the mental function and psychological competence. Even though there is no cure for Alzheimer’s, current treatment patterns and research aim to delay the progression towards dementia and the associated symptoms. The strongest risk factor for this disease is increased age, typically seen in individuals over the age of 65, but it must be noted that Alzheimer’s is not a normal part of the aging process.

Alzheimer’s disease is the top 10 fatal diseases that doesn’t have a cure, no means of prevention, and no disease-modifying treatment. Alzheimer’s disease isn’t just a disease that affects older aged people, there have been hundred, maybe even thousands of patients who have shown symptoms of Alzheimer’s during their 40’s, 50’s, or even in their 30’s. Although it is just about 5% of the time, whenever this happens to someone it’s referred as Alzheimer’s early on-set. In addition, about 700,000 people die from Alzheimer’s and dementia; this makes it the third leading cause of death behind cancer and heart disease. Unfortunately, the only thing we have against Alzheimer’s are treatments that help slow down the symptoms

With the growing number of people becoming diagnosed, and experiencing symptoms of Alzheimer’s disease, we must begin to take precautions and somehow attempt to gain knowledge of how the disease can be better treated, and ultimately prevented.

Alzheimer’s disease, considered the most common form of dementia, is a degenerative brain disorder which leads to loss of memory and decline of cognitive thinking. Alzheimer’s disease effects over 5 million Americans, a number which is expected to triple in the projected future, and is the sixth leading cause of death in the United States (Dougherty, R.J., et al). Majority of these affected people are sixty-five years of age or older and have what is called late-onset Alzheimer’s, whilst a smaller margin of individuals is younger than sixty-five years of age and are said to have early-onset Alzheimer’s. Alzheimer’s disease presents itself in three main stages, is caused by the degeneration of neurons and by the changes in protein composition in the brain, and despite the lack of definitive, early diagnosis or preventative treatment the disease can to a certain degree be detected and managed.

7- Acetyl Choline – chemical messenger in the brain which makes “neurones spark better and speak to each other more clearly.” (Bryden, 2005, p. 16) Small amounts of acetyl choline when you have dementia so brain does not work as fast. Drugs called acetyl cholinesterase (AChE) inhibitors stop the breakdown of acetyl choline so you have increased amounts in

Alzheimer’s disease is a type of dementia that gradually destroys brain cells, affecting a person’s memory and their ability to learn, make judgments, communicate and carry out basic daily activities. The disease is a progressive degenerative disease of the brain. It was first described by the German neuropathologist Alois Alzheimer in 1905 (Selkoe, 2016). The average life expectancy of an Alzheimers patient is between five and ten years, but some patients today have live for up to 15 years after the diagnosis due to improvements in care and medical treatments. The cause of Alzheimer 's has not yet been discovered and it also not possible to confirm a person has Alzheimer 's until their autopsy following death (Park, 2016).

Unfortunately the most accurate diagnosis of Alzheimer’s disease is by postmortem examination of the brain. The disease itself is not well defined, and its varied yet subtle manifestations lend difficulty in distinguishing it from other nervous system diseases or dementia-causing diseases. The danger exists that appropriate therapy that might bring relief or even cure, might be withheld from some patients if their conditions are misdiagnosed. Because, even though no effective treatment for AD is available, there are useful therapies for various diseases that produce symptoms of dementia (4).

In this experiment, the controlled variables were the age of the person, length of experiment,

Fragile X Syndrome is a genetic disorder that causes intellectual disability and is very common. The main characteristic is that children find it hard to process, understand information and work. You can identify fragile x syndrome is babies miss important developmental steps, or if their are noticeable physical traits like a different face or a big head circumference. This disability causes difficulty in learning, development and in their behaviour social/behavioural.

As the geriatric population continues to increase, there is a greater need for management of conditions commonly found in the population. One challenging health problem in the geriatric population is dementia. Dementia is a debilitating condition that affects many people worldwide, and the number of people suffering from dementia is expected to increase in coming years. According to Alzheimer’s Disease